Silvio Aime1, Mohammed Al-Qahtani2, Martin Behe3, Guy Bormans4, Giuseppe Carlucci5, Jean N DaSilva6, Clemens Decristoforo7, Adriano Duatti8, Philip H Elsinga9, Klaus Kopka10, Xiang-Guo Li11, Zhibo Liu12, Robert H Mach13, Oskar Middel14, Jan Passchier15, Marianne Patt16, Ivan Penuelas17, Ana Rey18, Peter J H Scott19, Sergio Todde20, Jun Toyohara21, Danielle Vugts22, Zhi Yang23. 1. University of Torino, Torino, Italy. 2. King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia. 3. Paul Scherrer Institute, Villigen, Switzerland. 4. Katholieke Universiteit Leuven, Leuven, Belgium. 5. UCLA Molecular and Medical Pharmacology Department, Los Angeles, USA. 6. University of Montreal, Montreal, Canada. 7. Universitaetsklinikum fur Nuclearmedizin, Innsbruck, Austria. 8. University of Ferrara, Ferrara, Italy. 9. University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. 10. Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany. k.kopka@hzdr.de. 11. Turku PET-center, Turku, Finland. 12. Peking University, Beijing, China. 13. University of Pennsylvania, Philadelphia, USA. 14. St. Olavs Hospital, Trondheim, Norway. 15. Invicro, London, UK. 16. University of Leipzig, Leipzig, Germany. 17. University Clinic of Navarra, Pamplona, Spain. 18. Universidad de la Republica, Montevideo, Uruguay. 19. University of Michigan, Ann Arbor, USA. 20. University of Milano-Bicoccia, Milan, Italy. 21. Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan. 22. Amsterdam UMC, Amsterdam, The Netherlands. 23. Peking University Cancer Hospital, Beijing, China.
Abstract
BACKGROUND: The Editorial Board of EJNMMI Radiopharmacy and Chemistry releases a biyearly highlight commentary to update the readership on trends in the field of radiopharmaceutical development. RESULTS: This commentary of highlights has resulted in 23 different topics selected by each member of the Editorial Board addressing a variety of aspects ranging from novel radiochemistry to first in man application of novel radiopharmaceuticals. CONCLUSION: Trends in radiochemistry and radiopharmacy are highlighted demonstrating the progress in the research field being the scope of EJNMMI Radiopharmacy and Chemistry.
BACKGROUND: The Editorial Board of EJNMMI Radiopharmacy and Chemistry releases a biyearly highlight commentary to update the readership on trends in the field of radiopharmaceutical development. RESULTS: This commentary of highlights has resulted in 23 different topics selected by each member of the Editorial Board addressing a variety of aspects ranging from novel radiochemistry to first in man application of novel radiopharmaceuticals. CONCLUSION: Trends in radiochemistry and radiopharmacy are highlighted demonstrating the progress in the research field being the scope of EJNMMI Radiopharmacy and Chemistry.
Authors: Sofie Celen; Johanna Rokka; Tonya M Gilbert; Michel Koole; Isabeau Vermeulen; Kim Serdons; Frederick A Schroeder; Florence F Wagner; Tom Bleeser; Baileigh G Hightower; Jiyun Hu; Dania Rahal; M Hassan Beyzavi; Wim Vanduffel; Koen Van Laere; Janice E Kranz; Jacob M Hooker; Guy Bormans; Christopher J Cawthorne Journal: ACS Chem Neurosci Date: 2020-03-19 Impact factor: 4.418
Authors: Martin G Strebl; Changning Wang; Frederick A Schroeder; Michael S Placzek; Hsiao-Ying Wey; Genevieve C Van de Bittner; Ramesh Neelamegam; Jacob M Hooker Journal: ACS Chem Neurosci Date: 2015-12-21 Impact factor: 4.418
Authors: Falguni Basuli; Xiang Zhang; Tim E Phelps; Elaine M Jagoda; Peter L Choyke; Rolf E Swenson Journal: Molecules Date: 2020-08-27 Impact factor: 4.411